Editorial
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. Jan 26, 2025; 17(1): 101153
Published online Jan 26, 2025. doi: 10.4330/wjc.v17.i1.101153
Umbilical cord-derived mesenchymal stromal cells: Promising therapy for heart failure
Ya-Lun Li, En-Guo Chen, Bing-Bing Ren
Ya-Lun Li, En-Guo Chen, Bing-Bing Ren, Department of Pulmonary and Critical Care Medicine, Regional Medical Center for National Institute of Respiratory Disease, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, Zhejiang Province, China
Ya-Lun Li, Medical College, Zhejiang University, Hangzhou 310063, Zhejiang Province, China
Co-corresponding authors: En-Guo Chen and Bing-Bing Ren.
Author contributions: Li YL and Ren BB designed the overall concept and outline of the manuscript; Chen EG contributed to the discussion and design of the manuscript; Li YL, Chen EG, and Ren BB contributed to the writing, and editing of the manuscript; Chen EG and Ren BB designed and revised the manuscript, and supervised the whole process of the project, they are the co-corresponding authors of this manuscript; and all authors have read and approved the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bing-Bing Ren, PhD, Associate Professor, Department of Pulmonary and Critical Care Medicine, Regional Medical Center for National Institute of Respiratory Disease, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, No. 3 East Qingchun Road, Hangzhou 310016, Zhejiang Province, China. renbb@ustc.edu.cn
Received: September 5, 2024
Revised: November 6, 2024
Accepted: December 2, 2024
Published online: January 26, 2025
Processing time: 137 Days and 20.8 Hours
Core Tip

Core Tip: There has been increased emphasis on the efficacy and potential of umbilical cord-derived mesenchymal stromal cells (UC-MSCs) for reversing cardiac remodeling in heart failure. UC-MSCs exhibit low immunogenicity and tumorigenicity, with a painless, non-invasive collection process. Compared to bone marrow-derived mesenchymal stromal cells, UC-MSCs exhibit superior proliferation, migration, immunosuppressive effects, and paracrine activity. However, their efficacy largely depends on the primitive source and extraction/delivery methods. Therefore, optimizing extraction/delivery techniques and conducting rigorous clinical trials are essential for further clinical implementation of UC-MSCs in heart failure patients.